It discusses the etiology, histogenesis, clinical features of AtLP and their separation from malignant lymphomas. It also presents case series illustrating this category. Table 2. Distinction ...

In a major step toward democratizing access to advanced healthcare, Burjeel Holdings, a leading super-specialty healthcare ...

“We’re advancing REC-3565, a potential best-in-class MALT1 inhibitor, to improve outcomes for patients with B-cell malignancies with limited treatment options,” said David Mauro, Chief Medical Officer ...

clonoSEQ testing for patients with MCL is currently available for clinical use as a laboratory-developed test performed at ...

Castleman disease is an idiopathic, rare lymphoproliferative disorder. It is classified as multicentric Castleman disease, ...

REC-3565 is a mucosa-associated lymphoid tissue lymphoma translocation protein ... MALT1, a key protease in the NF-kB pathway, drives malignant B-cell proliferation in hematological cancers.

NX-5948 assigned the nonproprietary name “bexobrutideg”U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström ...

Minister of Health Dr. Ahmad Al-Awadhi stated that Kuwait's medical system has seen significant progress in recent years, ...

An NHS doctor has warned that there are some 'unexplained' early symptoms of cancer that you should be aware of, encouraging people to speak to their GP if they're concerned ...

An NHS doctor has shared that there's no point 'sitting at home, fretting' about the symptoms you have - it's always best to ...